[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gynecologic-cancers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gynecologic-cancers":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,26,0,25,[9,54,84,117,147,168,193,241,265,292,331,362,387,408,434,462,490,519,548,574,615,636,657,689,720],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100617070","comparison-of-self-locking-versus-traditional-sutures-in-double-layer-laparoscopic-vaginal-vault-closure-after-hysterectomy-bi-sure-trial-100617070",false,"NCT07313839","Comparison of Self-Locking Versus Traditional Sutures in Double-Layer Laparoscopic Vaginal Vault Closure After Hysterectomy (BI-SURE Trial)","Comparison Between Double-Layer Self-Locking and Traditional Sutures in Post-Hysterectomy Laparoscopic Colporrhaphy: A Multicenter Pragmatic Randomized Controlled Trial","BI-SURE","Inclusion Criteria:\n\n* Patients undergoing laparoscopic or robotically assisted hysterectomy for gynecologic malignant disease\n* Age ≥ 18 years\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Laparotomic or vaginal hysterectomy\n* Contraindication to laparoscopic vaginal vault closure","FEMALE","18 Years",{"count":21,"type":22},310,"ESTIMATED","INTERVENTIONAL",[25],"NA","Vaginal vault closure after laparoscopic or robotic hysterectomy may be associated with postoperative complications such as vaginal cuff dehiscence, infection, and bleeding. The optimal suture material and technique for laparoscopic colporrhaphy, particularly in patients undergoing surgery for gynecologic malignancies, remain controversial.\n\nThe BI-SURE trial is a multicenter, randomized controlled study designed to compare double-layer self-locking sutures versus double-layer traditional Polyglactin 910 sutures for laparoscopic vaginal vault closure after hysterectomy. The study aims to evaluate postoperative effectiveness and safety within three months after surgery.",[28,29,30],"Gynecologic Cancers","Vaginal Cuff Dehiscence","Postoperative Complications",[32,33,34,35,36,37,38,39,40],"Laparoscopic hysterectomy","Vaginal vault closure","Colporrhaphy","Self-locking suture","Barbed suture","Polyglactin 910","Gynecologic oncology","Postoperative complications","Randomized controlled trial","RECRUITING","2026-06-16",{"date":44,"type":45},"2026-06-17","ACTUAL",{"date":47,"type":45},"2025-10-07",{"date":49,"type":22},"2027-01",{"name":51,"class":52},"Azienda Ospedaliero-Universitaria di Parma","OTHER",5,{"id":55,"slug":56,"hasResults":12,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":23,"phases":64,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100642837","a-modular-cloud-platform-for-fertility-preservation-100642837","NCT07642531","A Modular Cloud Platform For Fertility Preservation","A Modular CLoud Based Platform To Enhance Fertility Preservation Awareness: Design, Pilot Testing And Randomized Controlled Trial","Inclusion Criteria:\n\n* Women of reproductive age between the ages of 18 and 45,\n* Diagnosed with early stage cervical cancer, ovarian cancer, tubal cancer and endometrial cancer and whose treatment has not started,\n* Those who have a smartphone and can use the platform,\n* Volunteering and giving informed consent,\n* Turkish literate,\n* Individuals who do not report mental problems\n* Do not have children,\n* Marital status is married or single.\n\nExclusion Criteria:\n\n* Neurological disease (e.g., stroke, multiple sclerosis) or cognitive impairment,\n* Advanced-stage gynecologic cancers,\n* Failure to complete the follow-up period,\n* Initiation of oncologic treatment during the study period,\n* Non-completion or incomplete completion of the data collection instruments,\n* Non-use of the platform among participants allocated to the intervention group,\n* History of prior cancer treatment.","45 Years",{"count":63,"type":22},140,[25],"The research was designed as a randomized controlled study to determine the effectiveness of a modular cloud-based training platform in increasing awareness of fertility preservation.\n\nThe study aims to develop a free, modular, cloud-based, sustainable digital platform to increase fertility awareness. The platform will provide basic information on fertility preservation methods in plain language to support informed decisions. Content will be based on European Society of Human Reproduction and Embryology (ESHRE) , International Federation of Gynaecology and Obstetrics (FIGO) and Asian Society of Gynecologic Oncology (ASCO) guidelines. The study targets not only cancer patients but also women requesting fertility preservation for medical or social reasons.\n\nIn the first stage, the platform will be designed with the ADDIE instructional design model (Analysis, Design, Development, Implementation, Evaluation) and content created per international guidelines. In the second stage, the prototype will be pilot-tested and revised. In the third stage, effectiveness will be tested through a randomized controlled trial. Educational modules will be provided to the intervention group, while the control group will receive brochures. The study will include women aged 18-45 with early-stage gynecological cancer (cervix, ovary, tube, endometrium) at Prof. Dr. Cemil Tascioglu City Hospital, untreated. Participants must have Turkish literacy and internet access. Sample size, calculated with G\\*Power, is 140 total (70 per group).",[67,28],"Fertility Preservation",[69,70,71,72],"fertility","gynecologic cancer","fertility preservation","mobile application","NOT_YET_RECRUITING","2026-06-11",{"date":76,"type":45},"2026-06-12",{"date":78,"type":22},"2026-09-02",{"date":80,"type":22},"2027-01-01",{"name":82,"class":52},"Biruni University",1,{"id":85,"slug":86,"hasResults":12,"nctId":87,"briefTitle":88,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":12,"sex":90,"minAge":19,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":95,"conditions":96,"keywords":99,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":83},"100595982","phase-2-single-dose-investigator-initiated-pilot-study-to-investigate-cytalux-pafolacianine-for-intraoperative-detection-of-malignant-tissue-in-subjects-undergoing-surgical-resection-for-cancer-100595982","NCT07039526","Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer.","Inclusion Criteria:\n\n1. Male and Female patients 18 years of age and older\n2. Have a primary diagnosis, or a high clinical suspicion, of gastrointestinal, fore gut, pancreatic, hepatobiliary, esophageal malignancies and gyn malignancies planned for HIPEC\u002Fdebulking, warranting surgery.\n3. Are scheduled to undergo surgical intervention for tumor resection or diagnostic laparoscopy for assessment of disease burden.\n4. Willingness to stop the use of folate, folic acid, or folate-containing supplements within 48 hours before administration of Cytalux\n5. Willingness of research participant or legal guardian\u002Frepresentative to give written informed consent.\n\nExclusion Criteria:\n\n1. Any medical condition that in the opinion of the investigators could potentially jeopardize the safety of the subject\n2. History of anaphylactic reactions to products containing indocyanine green for near infrared imaging. Subjects with a medical history of 'idiopathic anaphylaxis' will require evaluation.\n3. History of allergy to any of the components of CYTALUX™ (pafolacianine) injection\n4. Presence of any psychological, familial, sociological condition or geographical challenges potentially hampering compliance with the study protocol or follow-up schedule","ALL",{"count":92,"type":22},50,[94],"PHASE2","The goal of clinical trial is to test an FDA approved drug called Pafolacianine that attaches to cancer cells and lights up when seen through a special camera system in adults with a suspected primary diagnosis, or a high clinical suspicion of gastrointestinal, fore gut, pancreatic, hepatobiliary, esophageal malignancies and gyn malignancies planned for HIPEC\u002Fdebulking, warranting surgery. The main question it aims to answer is:\n\n• Can CYTALUX™ (pafolacianine) injection used with near-infrared (NIR) fluorescent imaging improve the detection of malignant tissue in subjects undergoing surgical resection for cancer? Participants taking part in this study will receive the study medication. Then, during the surgery the investigator team will turn on the camera to evaluate if the tumor is visible with the help of the study medication. Taking part in this study will last about 2 months.",[97,98,28],"Esophageal Cancer","Gastrointestinal Cancers",[100,101,102,103,104,105,106,107],"Pafolacianine","CYTALUX","Folate receptor-alpha","Near-infrared fluorescence imaging","Intraoperative imaging","Fluorescence-guided surgery","esophageal cancer","gastrointestinal cancer","2026-06-03",{"date":110,"type":45},"2026-06-05",{"date":112,"type":45},"2025-08-19",{"date":114,"type":22},"2027-12",{"name":116,"class":52},"John Waters",{"id":118,"slug":119,"hasResults":12,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":23,"phases":126,"briefSummary":127,"conditions":128,"keywords":132,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":146},"100594848","phase-2-a-study-to-assess-change-in-disease-activity-and-adverse-events-in-adult-participants-with-gynecologic-cancers-receiving-intravenous-infusion-of-imgn151-as-monotherapy-or-in-combination-with-other-therapies-100594848","NCT07024784","A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies","A Phase 1b Dose Escalation and Expansion Study of IMGN151 as Monotherapy and in Combination With Other Anti-Cancer Therapies in Subjects With Gynecologic Cancers","Inclusion Criteria:\n\n* ECOG performance status of 0 or 1\n* Participants (except for platinum-sensitive ovarian, fallopian tube, and primary peritoneal cancer (PSOC) participants without disease progression after platinum combination standard of care therapy in Arms B and D) will have ≥ 1 lesion that meets the definition of measurable disease by RECIST v1.1 (radiographically measured by the investigator).\n* Participants will have high-grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers (EOC).\n* Participant has completed prior therapy within the specified times below:\n\n  * Systemic antineoplastic therapy within 5 half-lives or 4 weeks (whichever is shorter) prior to the first dose of IMGN151.\n  * Focal radiation completed ≥ 2 weeks prior to the first dose of study treatment.\n\nExclusion Criteria:\n\n* Participants with ovarian cancer with histologies including: endometrioid, clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of the above histologies, as well a low-grade or borderline ovarian tumor.\n* History of clinically significant medical conditions or any other reason that the investigator determines would interfere with the participant's participation in this study or would make the participant an unsuitable candidate to receive study treatment.\n* Prior treatment with FRα-targeting therapy.\n* Prior wide-field radiotherapy affecting more than 20% of the bone marrow.",{"count":125,"type":22},377,[94],"Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety and tolerability of IMGN151 when given as monotherapy and in combination with other anti-cancer therapies in adult participants with gynecologic cancers.\n\nIMGN151 is an investigational drug being developed for the treatment of gynecologic cancers. Participants are placed in 1 of 4 groups, called treatment arms. Each group receives a different treatment. Around 377 participants with gynecologic cancers will be enrolled in the study at approximately 50 sites worldwide.\n\nParticipants will receive intravenous infusions of IMGN151 as monotherapy or in combination with anti-cancer therapies according to their assigned study arm. In Arm A, participants will receive IMGN151 in combination with carboplatin on Day 1 of each cycle. In Arm B, participants will receive IMGN151 in combination with olaparib, twice a day (BID) on Day 1 of each cycle. In Arm C, participants will receive IMGN151 in combination with bevacizumab on Day 1 of each cycle. In Arm D, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. In Arm E, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. In Arm F, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. The total study duration will be approximately 3 years.\n\nThere may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.",[28,129,130,131],"Platinum-Sensitive Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Cancer (PSOC)",[28,129,133,130,131,134,135],"Platinum-Resistant Ovarian Cancer","Cancer","IMGN151","2026-05-29",{"date":138,"type":45},"2026-06-02",{"date":140,"type":45},"2025-07-30",{"date":142,"type":22},"2028-02",{"name":144,"class":145},"AbbVie","INDUSTRY",16,{"id":148,"slug":149,"hasResults":12,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":23,"phases":156,"briefSummary":157,"conditions":158,"keywords":159,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":161,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":83},"100585590","communication-about-sexual-health-in-gynecologic-cancer-100585590","NCT06904339","Communication About Sexual Health in Gynecologic Cancer","Promoting Effective Clinical Communication About Sexual Health After Gynecologic Cancer: A Randomized Controlled Trial of a Patient-Focused Intervention","Inclusion Criteria:\n\n* At least 18 years old\n* Diagnosed with any stage (I-IV) gynecologic cancer\n* Receiving treatment for gynecologic cancer or completed active treatment less than 10 years ago\n* Attending visits in follow-up care at Fox Chase Cancer Center\n* Score of at least 3 on a sexual concerns screener question\n\nExclusion Criteria:\n\n* Not able to speak English\n* Not willing to have clinic visit audio recorded\n* Eastern Cooperative Oncology Group (ECOG) score \\> 2\n* Overt cognitive dysfunction or psychiatric disturbance",{"count":155,"type":22},200,[25],"The goal of this clinical trial is to learn if an educational video and workbook can help gynecologic cancer patients talk to their cancer providers about sexual health concerns.\n\nThe main questions it aims to answer are:\n\n1. Do gynecologic cancer patients who take part in the educational program and get a resource booklet talk to their cancer clinicians more about sexual health concerns than patients who get a resource booklet alone?\n2. Do gynecologic cancer patients who take part in the educational program and get a resource booklet have better sexual function and less anxiety and depression than patients who get a resource booklet alone?\n\nResearchers will compare those who get the educational program and the resource booklet to those who get the resource booklet alone along with their usual care.\n\nParticipants will:\n\n1. Fill out a consent form and survey\n2. Have their next clinic visit audio recorded\n3. Fill out another survey right after their clinic visit\n4. Fill out a final survey 6 months after their clinic visit",[28],[160],"sexual health",{"date":138,"type":45},{"date":163,"type":45},"2025-02-20",{"date":165,"type":22},"2028-09-30",{"name":167,"class":52},"Fox Chase Cancer Center",{"id":169,"slug":170,"hasResults":12,"nctId":171,"briefTitle":172,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":176,"phases":4,"briefSummary":177,"conditions":178,"keywords":182,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":83},"100135545","genetic--pathological-studies-of-brca1brca2-associated-tumors--blood-samples-100135545","NCT01034033","Genetic & Pathological Studies of BRCA1\u002FBRCA2: Associated Tumors & Blood Samples","Inclusion Criteria:\n\nI. Women who have a high risk of developing breast or ovarian cancer due to a known germline mutation in the BRCA1\u002F2, PTEN, CDH1, or TP53 cancer susceptibility genes, or due to strong family history of either breast or ovarian cancer, in the absence of known cancer susceptibility gene mutation.\n\nII. Women who are approaching surgery for resection of a pelvic mass, which is considered suspicious for neoplasia by radiologic or clinical criteria; such women may or may not also meet criteria for inclusion in group I.",{"count":175,"type":22},3300,"OBSERVATIONAL","The purpose of this study is to try to understand the biology of development of breast, ovarian, fallopian tube, peritoneal or endometrial cancer from persons at high genetic risk for these diseases. The influence of environmental factors on cancer development in individuals and families will be studied. The efficacy of treatments for these diseases will be evaluated.",[179,180,28,181],"Breast Cancer","Ovarian Cancer","Ovarian\u002FPeritoneal\u002FFallopian Cancer",[183],"quality of life","2026-05-14",{"date":186,"type":45},"2026-05-18",{"date":188,"type":4},"2001-08",{"date":190,"type":22},"2099-01",{"name":192,"class":52},"Stanford University",{"id":194,"slug":195,"hasResults":12,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":12,"sex":90,"minAge":19,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":23,"phases":203,"briefSummary":204,"conditions":205,"keywords":212,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":83},"100638121","phase-2-romiplostim-n01-plus-atra-for-persistent-isolated-chemotherapy-induced-thrombocytopenia-after-complete-remission-of-gynecologic-breast-or-lung-solid-tumors-100638121","NCT07586826","Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors","A Prospective, Randomized, Open-Label, Controlled Study of Romiplostim N01 Combined With All-Trans Retinoic Acid Versus Romiplostim N01 Alone for Persistent Isolated Chemotherapy-Induced Thrombocytopenia in Patients With Complete Remission of Gynecologic, Breast, or Lung Solid Tumors","N01-A-PICIT-GT","Inclusion Criteria:\n\n1. Age 18 years or older.\n2. Prior diagnosis of a selected gynecologic, breast, or lung solid tumor, including but not limited to non-small cell lung cancer (NSCLC), ovarian cancer, or breast cancer. Other eligible tumor types may include endometrial cancer, cervical cancer, fallopian tube cancer, primary peritoneal cancer, and other lung cancers, if clinically appropriate and if all other eligibility criteria are met.\n3. Complete remission of the underlying tumor after chemotherapy or antitumor treatment, with tumor-related treatment discontinued for at least 12 weeks before enrollment, no evidence of recurrence or progression by specialist assessment, and no current need for additional tumor-directed therapy.\n4. Persistent isolated chemotherapy-induced thrombocytopenia, defined as platelet count \\\u003C30 x 10\\^9\u002FL on two peripheral blood tests at least 7 days apart; or platelet count slightly higher than 30 x 10\\^9\u002FL with dependence on platelet transfusion to maintain a safe platelet level.\n5. Thrombocytopenia has persisted since the last chemotherapy treatment without a clear trend of spontaneous recovery.\n6. Red blood cell count and neutrophil count are generally preserved, without clinically significant anemia or neutropenia.\n7. Bone marrow assessment performed within 1 year after tumor diagnosis and chemotherapy shows no tumor cell infiltration; megakaryocyte count is normal or increased, with or without maturation impairment.\n8. No hepatosplenomegaly, portal hypertension, or other evidence suggesting abnormal platelet redistribution as the main cause of thrombocytopenia.\n9. Prior treatment with at least one thrombopoietin receptor agonist or recombinant human thrombopoietin for PICIT without response, defined as failure of platelet count to rise to a safe level or to at least 2 times baseline after at least 2 weeks of standard-dose treatment.\n10. No prior use of Romiplostim N01.\n11. Other platelet-raising medications have been discontinued before enrollment. No washout period is required for prior thrombopoietin receptor agonists; other investigational drugs or off-label treatments must be discontinued for at least 1 month before enrollment.\n12. Ability to understand and sign the informed consent form and willingness to comply with study visits and procedures.\n13. Participants of reproductive potential must agree to use effective contraception during study treatment. Female participants of childbearing potential must have a negative pregnancy test before enrollment.\n\nExclusion Criteria:\n\n1. Other hematologic diseases that may affect hematopoiesis or cause thrombocytopenia, including but not limited to aplastic anemia, myelodysplastic syndrome, leukemia or other hematologic malignancies, or a clear history of primary immune thrombocytopenia.\n2. Active recurrence or progression of the underlying tumor, or evidence of bone marrow metastasis or tumor cell infiltration on bone marrow examination.\n3. Uncontrolled chronic viral infection, including hepatitis B, hepatitis C, or HIV infection, or active severe infection at screening or within 4 weeks before screening.\n4. Severe cardiac, hepatic, renal, or other organ dysfunction, or any serious organic disease that would make the participant unable to tolerate study treatment.\n5. Pregnancy or breastfeeding.\n6. Known severe hypersensitivity to Romiplostim, Romiplostim N01, ATRA, or any component of the study drugs.\n7. Prior Romiplostim treatment associated with severe adverse reactions or lack of efficacy.\n8. Poor compliance, inability to complete treatment or follow-up, psychiatric or psychological condition that prevents understanding of the study procedures, or any other condition that, in the investigator's judgment, may increase study risk or interfere with interpretation of study results.",{"count":202,"type":22},220,[94],"This is a prospective, randomized, open-label, active-controlled study to evaluate the efficacy and safety of Romiplostim N01 plus all-trans retinoic acid (ATRA) compared with Romiplostim N01 alone in adults with persistent isolated chemotherapy-induced thrombocytopenia (PICIT) after complete remission of selected gynecologic, breast, or lung solid tumors, including but not limited to non-small cell lung cancer (NSCLC), ovarian cancer, and breast cancer.\n\nEligible participants will be randomized in a 1:1 ratio to receive Romiplostim N01 plus oral ATRA or Romiplostim N01 alone for 12 weeks, with follow-up through Week 24. The primary outcome is the overall platelet response rate at Week 12, defined as platelet count \\>50 x 10\\^9\u002FL in at least 2 of the last 3 scheduled platelet assessments up to Week 12. Secondary outcomes include sustained response during Weeks 13 to 24, complete and partial response rates, duration of response, time to response, platelet count changes, platelet transfusion requirements, bleeding events, and safety.",[206,207,28,180,179,208,209,210,130,211],"Persistent Isolated Chemotherapy-Induced Thrombocytopenia","Chemotherapy-Induced Thrombocytopenia","Lung Cancer","Non-Small Cell Lung Cancer","Cervical Cancer","Primary Peritoneal Cancer",[213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,229,230,231,232,211,130],"PICIT","Persistent isolated chemotherapy-induced thrombocytopenia","CIT","Chemotherapy-induced thrombocytopenia","Romiplostim N01","ATRA","All-trans retinoic acid","Tretinoin","Thrombopoietin receptor agonist","Gynecologic cancer","Ovarian cancer","Breast cancer","Lung cancer","NSCLC","Non-small cell lung cancer","Endometrial cancer","Cervical cancer","Complete remission","Platelet response","Thrombocytopenia","2026-05-08",{"date":184,"type":45},{"date":236,"type":45},"2025-12-22",{"date":238,"type":22},"2027-12-31",{"name":240,"class":52},"Peking University People's Hospital",{"id":242,"slug":243,"hasResults":12,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":247,"eligibilityCriteria":248,"healthyVolunteers":12,"sex":90,"minAge":19,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":23,"phases":251,"briefSummary":252,"conditions":253,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":4},"100639132","quality-and-safety-of-real-time-brachytherapy-treatments-clinical-implementation-of-a-multipoint-scintillation-detector-for-treatment-monitoring-100639132","NCT07580651","Quality and Safety of Real-Time Brachytherapy Treatments: Clinical Implementation of a Multipoint Scintillation Detector for Treatment Monitoring","In Vivo Surveillance of Brachytherapy Using Plastic Scintillation Dosimetry: A Clinical Feasibility Study","(CurieInVivo)","Inclusion Criteria:\n\n* Patients receiving prostate brachytherapy treatment, or female user receiving gynecological brachytherapy treatment for cervical cancer.\n\nExclusion Criteria:\n\n* Patients with a Clostridium difficile infection or any other high-risk positive infection.",{"count":250,"type":22},20,[25],"This project addresses a key safety gap in High-Dose-Rate (HDR) brachytherapy, where very high, localized radiation doses mean that small geometric deviations in catheter placement or radioactive source positioning can cause clinically significant errors. Incident reports from the Radiation Oncology Incident Learning System (RO-ILS) of the American Society for Radiation Oncology (ASTRO) and guidelines from the American Association of Physicists in Medicine Task Group 59 (AAPM TG-59) identify these events-often occurring between imaging and treatment delivery-as among the most critical. Unlike external beam radiotherapy, brachytherapy lacks a prior phantom-based verification step, making in vivo dosimetry the only real-time method to confirm delivered dose and detect anomalies in dwell time or source position. International bodies such as the International Atomic Energy Agency (IAEA) recommend this approach for quality management and accident prevention.\n\nMultipoint plastic scintillation detectors (mPSD) offer water-equivalent, real-time measurements and can enable three-dimensional (3D) radioactive source tracking, but their clinical use remains limited due to integration challenges and the absence of well-defined alert thresholds.\n\nThe project aims to implement a real-time in vivo monitoring solution using an mPSD at the Centre régional intégré de cancérologie (CRIC) of Lévis, Québec (QC) for HDR gynecological and prostate brachytherapy. Objectives include: (1) demonstrating clinical feasibility and integration within existing clinical workflows; (2) validating the accuracy and precision of dose, dwell-time, and source-position measurements under clinical conditions; and (3) developing practical alert thresholds to identify common deviations. The central hypothesis is that mPSD technology can provide reliable, reproducible real-time measurements without lengthening procedures or disrupting clinical workflow.\n\nThe methodology relies on adapting the HYPERSCINT® platform for HDR in vivo use. A custom mPSD, consisting of several scintillators along a single optical fiber, will be insertable into a 6-French (6F) catheter.\n\nPhase 1 focuses on feasibility and integration, including HDR-specific calibration, definition of detector insertion scenarios, integration of acquisition hardware, and staff training.\n\nPhase 2 validates performance in at least 20 patients. Planned treatment parameters and time-stamped detector signals acquired at 1-10 hertz (Hz) will be used to reconstruct delivered dose, dwell times, and source-to-detector distances. Measurement accuracy and reproducibility will be quantified using mixed-effects statistical models.\n\nPhase 3 establishes preliminary alert thresholds based on deviations in dose, time, and position, along with visualization tools such as Bland-Altman plots, although these thresholds will not be applied clinically during the study.\n\nExpected outcomes include demonstrated feasibility of in vivo mPSD monitoring, quantitative performance metrics with confidence intervals, identification of influential factors and operational recommendations, preliminary alert thresholds with reporting templates, and a roadmap for sustainable deployment in Lévis and other centers. Scientific outputs will also be produced for dissemination across the Santé Québec network.",[254,28],"Prostate Cancer","2026-05-05",{"date":257,"type":45},"2026-05-12",{"date":259,"type":22},"2027-01-15",{"date":261,"type":22},"2028-05-01",{"name":263,"class":264},"CISSS de Chaudière-Appalaches","OTHER_GOV",{"id":266,"slug":267,"hasResults":12,"nctId":268,"briefTitle":269,"officialTitle":269,"acronym":270,"eligibilityCriteria":271,"healthyVolunteers":12,"sex":90,"minAge":19,"maxAge":272,"enrollmentInfo":273,"targetDuration":4,"studyType":176,"phases":4,"briefSummary":274,"conditions":275,"keywords":277,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":291},"100635796","assessment-of-sexual-well-being-in-patients-with-gynecologic-cancer-and-their-partners-the-oncosex-study-100635796","NCT07557342","Assessment of Sexual Well-being in Patients With Gynecologic Cancer and Their Partners: the ONCOSEX Study","ONCOSEX","Inclusion Criteria:\n\n* Patients diagnosed with gynecological cancer: malignant ovarian tumor, ovarian tumor of uncertain behavior, cervical cancer, endometrial cancer, uterine sarcoma, vulvar cancer, vaginal cancer\n* Sexually active\n* Women who have a partner\n* Aged between 18 and 75\n* Women of any sexual orientation\n* Understanding and knowledge of the Italian language\n* Signing of the informed consent form\n* Signing of the informed consent form by the partner\n\nExclusion Criteria:\n\n* Benign gynecological conditions\n* Age \\\u003C 18 or \\> 75\n* Virgins or women who are no longer sexually active\n* Women with psychiatric or neurological disorders\n* Women or partners who have already undergone sexual counseling or sex therapy\n* Women who are unable to sign the informed consent form for the study","75 Years",{"count":155,"type":22},"Study type and design This is an observational, exploratory, prospective, longitudinal (cohort), multicenter, non-profit study. Its purpose is to observe changes in sexual function over time without modifying standard clinical care pathways.\n\nBackground and rationale Sexual dysfunctions and the psychological impact of gynecological cancers are often underestimated in clinical practice, despite the World Health Organization recognizing sexual health as a fundamental right. Cultural, personal, and educational barriers frequently hinder an open and systematic discussion of sexual health.\n\nAvailable literature highlights a significant deterioration in sexual quality of life and couple relationships among these patients; however, clear guidance on validated assessment tools and structured sexual counseling pathways is still lacking.\n\nStudy objectives\n\nPrimary objective: to evaluate whether and how sexual function questionnaire scores in patients and their partners change over time at different assessment time points.\n\nSecondary objective: to identify the proportion of patients and partners who would perceive sexual counseling as useful, as well as the preferred timing for such support.\n\nEndpoints\n\nPrimary endpoint: variation in Female Sexual Function Index (FSFI) scores in female patients and International Index of Erectile Function (IIEF-15) scores in male partners between assessment time points (T0-T1, T1-T2, T0-T2).\n\nSecondary endpoint: perceived usefulness of sexual counseling support and preferred timing, based on questionnaire responses.\n\nProcedures and assessment timeline Patients are enrolled at the time of diagnosis communication (T0). The same questionnaire is administered again six months after the start of treatment (T1) and twelve months after completion of therapy or surgery (T2). Participation requires written informed consent, and all data are collected in a pseudo-anonymized format. Partners are enrolled and assessed at the same time points.\n\nAssessment tools\n\nPatients: the validated Female Sexual Function Index (FSFI) questionnaire, plus an additional structured section exploring sexual experience, satisfaction, and difficulties.\n\nPartners: the IIEF-15 questionnaire for male partners; for female partners, the same instruments used for patients are administered.\n\nCollected variables Sociodemographic and clinical data, lifestyle habits, sleep quality, marital status, parity, ongoing or previous therapies, and FSFI and IIEF-15 questionnaire scores.\n\nSample size A total of 200 patients and 200 corresponding partners are expected to be enrolled.\n\nStatistical analysis Data will be analyzed descriptively and longitudinally across the three time points. The primary analysis will use linear mixed-effects models for repeated measures, including random effects for subjects and fixed effects for time and relevant clinical covariates. Predefined subgroup analyses are planned. Statistical significance is set at p \\\u003C 0.05.",[276,28],"Sexual Wellness",[278,279,280,281],"gynecologic cancers","sexuality","partner","cancer survivors","2026-04-22",{"date":284,"type":45},"2026-04-29",{"date":286,"type":22},"2026-04",{"date":288,"type":22},"2028-04",{"name":290,"class":52},"Casa di Cura Dott. Pederzoli",6,{"id":293,"slug":294,"hasResults":12,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":298,"eligibilityCriteria":299,"healthyVolunteers":12,"sex":18,"minAge":300,"maxAge":301,"enrollmentInfo":302,"targetDuration":4,"studyType":23,"phases":303,"briefSummary":304,"conditions":305,"keywords":308,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":83},"100618092","effect-of-skin-closure-techniques-on-body-image-in-women-undergoing-gynecologic-surgery-100618092","NCT07327125","Effect of Skin Closure Techniques on Body Image in Women Undergoing Gynecologic Surgery","Effect of Skin Closure Techniques on Body Image and Mood in Gynecologic Oncology Patients","BISGO","Inclusion Criteria:\n\n* Female participants aged 18 years or older.\n* Patients scheduled for elective open gynecologic surgery for suspected or confirmed gynecologic malignancy.\n* Surgery planned to be performed via a vertical midline laparotomy incision.\n* Literate patients capable of reading, understanding, and completing the Body Image Scale (BIS) and Hospital Anxiety and Depression Scale (HADS).\n* Patients who provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* History of prior radiotherapy to the abdominal or pelvic region.\n* Patients currently receiving chronic immunosuppressive therapy.\n* Body Mass Index (BMI) less than 18 kg\u002Fm\\^2 or greater than 40 kg\u002Fm\\^2.\n* Presence of cognitive impairment, dementia, or Alzheimer's disease.\n* Major psychiatric disorders that prevent the patient from understanding or completing the questionnaires.\n* Patients undergoing emergency surgery.","17 Years","60 Years",{"count":63,"type":22},[25],"This randomized clinical trial investigates the impact of two different skin closure techniques on body image and mood in women undergoing surgery for gynecologic cancers.\n\nPatients undergoing elective surgery with a midline abdominal incision will be randomly assigned to one of two groups: 1. Interrupted Closure Group: The surgical incision is closed using either metal clips (staples) or separate mattress sutures (individual stitches). 2. Subcuticular Sutures Group: The surgical incision is closed using continuous stitches placed under the skin surface (aesthetic stitching).\n\nThe main goal of the study is to determine whether the method of wound closure affects a patient's perception of their body image, cosmetic satisfaction, and levels of anxiety or depression.\n\nAdditionally, the study aims to prove that the subcuticular suture technique is safe and does not increase the risk of wound complications (such as infection or wound separation) compared to the other method.\n\nParticipants will be asked to complete questionnaires before surgery, and again at 1, 3 and 6 months after surgery to track changes in their feelings and satisfaction with the scar.",[28,306,307],"Surgical Wound Closure Techniques","Body Image",[309,310,311,312,307,313,314,315,316,317,318,319,320,321],"surgical staples","Subcuticular Sutures","Gynecologic Oncology","Skin Closure Techniques","Surgical Wound","Laparotomy","Cicatrix","Anxiety","Depression","Midline Incision","Wound Dehiscence","Wound Complications","Surgical Site Infection","2026-04-12",{"date":324,"type":45},"2026-04-14",{"date":326,"type":45},"2026-01-01",{"date":328,"type":22},"2028-03-01",{"name":330,"class":264},"Başakşehir Çam & Sakura City Hospital",{"id":332,"slug":333,"hasResults":12,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":337,"eligibilityCriteria":338,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":339,"targetDuration":4,"studyType":23,"phases":341,"briefSummary":342,"conditions":343,"keywords":344,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":361},"100631217","mindfulness-based-psychoeducation-for-women-with-gynecological-cancer-100631217","NCT07497802","Mindfulness-Based Psychoeducation for Women With Gynecological Cancer","Effect of a Mindfulness-Based Psychoeducation Program on Hope, Cognitive-Emotional Coping With Cancer, Quality of Life, and Psychological Well-Being in Women With Gynecological Cancer: A Randomized Controlled Trial","MIND-GYN","Inclusion Criteria:\n\n* Women who voluntarily agree to participate in the study\n* Women aged 18 years and older\n* Women diagnosed with gynecological cancer and currently undergoing active treatment (e.g., surgery, chemotherapy, radiotherapy, immunotherapy, or targeted therapy)\n* Ability to participate in online sessions from home after hospital discharge\n* Ability to use a smartphone or similar device to access online sessions\n* Having at least basic literacy (able to read and write)\n* Expected life expectancy ≥ 12 months, as evaluated by the responsible oncologist\n\nExclusion Criteria:\n\n* Diagnosis of a psychiatric disorder that may interfere with participation\n* Current use of psychiatric medications\n* Previous participation in Mindfulness-Based Stress Reduction (MBSR) or similar mindfulness programs\n* Having a physical condition that prevents participation in the intervention sessions\n* Presence of communication barriers (e.g., inability to speak Turkish, severe hearing impairment)\n* Having a history of previous cancer diagnosis or metastatic disease\n* Participants who voluntarily withdraw from the study during the intervention period\n* Participation in less than 80% of the intervention sessions (attendance at fewer than 6 out of 8 sessions)\n* Discontinuation of treatment or death during the study period",{"count":340,"type":22},96,[25],"This randomized controlled study aims to evaluate the effect of a mindfulness-based psychoeducation program on hope, cognitive-emotional coping with cancer, quality of life, and psychological well-being in women diagnosed with gynecological cancer. Women receiving treatment for gynecological cancer will be randomly assigned to either an intervention group and a control group. The intervention group will participate in an 8-week mindfulness-based psychoeducation program delivered in small groups via online platforms under the guidance of the researcher. The program will include mindfulness practices such as breathing exercises, body scan, awareness exercises, and guided imagery techniques aimed at improving emotional coping and psychological well-being. The control group will receive usual care. Outcomes will be assessed at baseline, immediately after the intervention, and at 3- and 6-month follow-up assessments.",[28],[345,346,347,348,349,350,351],"Gynecologic Cancer","Mindfulness","Psychoeducation","Hope","Cancer Coping","Quality of Life","Psychological Well-Being","2026-03-23",{"date":354,"type":45},"2026-03-27",{"date":356,"type":22},"2026-04-01",{"date":358,"type":22},"2030-08-01",{"name":360,"class":52},"Ondokuz Mayıs University",2,{"id":363,"slug":364,"hasResults":12,"nctId":365,"briefTitle":366,"officialTitle":367,"acronym":368,"eligibilityCriteria":369,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":370,"targetDuration":4,"studyType":176,"phases":4,"briefSummary":371,"conditions":372,"keywords":373,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":83},"100630148","interest-in-nighttime-day-hospital-chemotherapy-infusions-among-gynecologic-cancer-patients-100630148","NCT07483905","Interest in Nighttime Day Hospital Chemotherapy Infusions Among Gynecologic Cancer Patients","Assessment of Interest Among Patients With Gynecologic Cancers in a Nighttime Day Hospital (DH) Service for Long-duration Chemotherapy Infusions: an Observational Study Based on an Anonymous Online Survey.","CHeMoON","Inclusion Criteria:\n\n* Female patients\n* aged 18 years or older\n* Diagnosis of a gynecologic cancer\n* Receiving care at the participating institution\n* Ability to independently understand and complete complete the anonymous online survey\n\nExclusion Criteria:\n\n* Inability to access or complete the online questionnaire or difficulty with reading and writing\n* Cognitive impairment\n* Patients currently hospitalized or in emergency settings.",{"count":155,"type":22},"This observational study aims to assess the interest of patients with gynecologic cancers in a nighttime Day Hospital service for the administration of long-duration chemotherapy infusions. An anonymous online survey will be distributed to eligible patients to evaluate their preferences, perceived benefits, and potential barriers related to receiving chemotherapy during nighttime hours. The results of this study will help inform the feasibility and acceptability of implementing a nighttime Day Hospital service for prolonged chemotherapy infusions.",[28],[374,375,376,377],"Long-duration Chemotherapy","Nighttime Day Hospital","Cancer Care Organization","Patient Preferences","2026-03-16",{"date":380,"type":45},"2026-03-19",{"date":382,"type":22},"2026-03-12",{"date":384,"type":22},"2026-07-01",{"name":386,"class":52},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":388,"slug":389,"hasResults":12,"nctId":390,"briefTitle":391,"officialTitle":391,"acronym":392,"eligibilityCriteria":393,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":394,"targetDuration":4,"studyType":23,"phases":396,"briefSummary":397,"conditions":398,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":83},"100602302","a-prospective-study-of-a-lifestyle-medicine-survivorship-program-for-patients-with-gynecologic-cancer-100602302","NCT07121738","A Prospective Study of a Lifestyle Medicine Survivorship Program for Patients With Gynecologic Cancer","HEAL-GYN","Inclusion Criteria:\n\n* Adult 18 years old or over\n* Diagnosis of gynecologic cancer\n* Current patient in the Central Florida area\n* Completing or have completed chemotherapy treatment within approximately the past 3 months before starting the program\n* Able to speak, read, and understand the English language.\n\nExclusion Criteria:\n\n* Not willing or able to provide informed consent\n* Not willing or able to comply with all study procedures and requirement for the duration of the study",{"count":395,"type":22},64,[25],"This study will examine the effects of an 8-week intervention called the Healthy Eating Active Lifestyle (HEAL)-GYN program on participants' 1) self-efficacy 2) lifestyle factors, including physical activity and diet, as well as mental health and overall well-being, and 3) biometrics and biomarkers.",[28],"2026-03-02",{"date":401,"type":45},"2026-03-03",{"date":403,"type":45},"2025-12-08",{"date":405,"type":22},"2026-08-31",{"name":407,"class":52},"AdventHealth",{"id":409,"slug":410,"hasResults":12,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":414,"eligibilityCriteria":415,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":416,"targetDuration":4,"studyType":23,"phases":418,"briefSummary":419,"conditions":420,"keywords":422,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":83},"100624219","phase-2-phase-ii-prospective-randomized-proof-of-concept-study-to-evaluate-the-effects-of-a-personalized-dietary-intervention-in-women-with-advanced-gynecologic-or-breast-tumors-treated-with-antibody-drug-conjugates-adcs-100624219","NCT07406789","Phase II, Prospective, Randomized, Proof-of-concept Study to Evaluate the Effects of a Personalized Dietary Intervention in Women With Advanced Gynecologic or Breast Tumors Treated With Antibody-Drug Conjugates (ADCs).","Phase II, Prospective, Randomized, Proof-of-Concept Study to Evaluate the Effects of a Personalized Dietary Intervention in Women With Advanced Gynecologic or Breast Tumors Treated With Antibody-Drug Conjugates (ADCs).","LUMInova","Inclusion Criteria:\n\n1. Written informed consent to participate in the study, obtained prior to performing any specific procedure.\n2. Women aged ≥ 18 years.\n3. Confirmed diagnosis of advanced, incurable (stage IV or unresectable stage III) breast cancer or gynecologic cancer. This includes cancers of the breast, ovary, cervix, uterus, endometrium, fallopian tubes, vagina, or vulva.\n4. Participants must have received a first cycle of ADC treatment in any line of treatment.\n5. ECOG performance status 0-2.\n6. Availability of their main clinical data with the possibility of follow-up.\n\nExclusion Criteria:\n\n1. Male patient.\n2. BMI \\\u003C18 or \\> 40 kg\u002Fm2.\n3. Patients with a life expectancy of less than 3 months.\n4. Type 1 diabetes mellitus, metabolic diseases, and severe gastrointestinal disorders that interfere with the digestion or absorption of nutrients, as well as patients with severe renal or hepatic impairment.\n5. Planned participation in treatment within a double-blind clinical trial.\n6. History of previous or concomitant malignant disease of any other type that could affect compliance with the protocol or interpretation of results. Patients with curatively treated basal cell carcinoma of the skin or in situ cervical cancer are eligible for the study.\n7. Presence of concurrent diseases or clinical conditions that, in the investigator's judgment, may significantly interfere with participation in the study, particularly those that limit the ability to adequately use the required digital tools (APP and wearable device). Patients will not be excluded due to common comorbidities if they retain adequate cognitive functioning and digital familiarity to comply with study procedures.\n8. Carriers of therapeutic electronic devices: pacemakers, defibrillators, and cardiac resynchronization devices (due to potential interference caused by the wearable).\n9. Patients who, in the investigator's judgment, do not possess sufficient digital capability to comply with the study procedures.",{"count":417,"type":22},100,[94],"The objective of the study is to evaluate the effect of a personalized dietary intervention (cohort A), compared with a standard nutritional intervention based on general recommendations for following a Mediterranean diet (cohort B), in women with advanced solid tumors of gynecologic or breast origin who are receiving treatment with antibody-drug conjugates (ADCs). This intervention is exclusively nutritional and does not involve the use of any investigational drug.",[28,421],"Advanced Breast Cancer",[224,423,134,424],"Diet","Gynecologic","2026-02-06",{"date":427,"type":45},"2026-02-12",{"date":429,"type":22},"2026-02-11",{"date":431,"type":22},"2028-02-11",{"name":433,"class":52},"TNC Nutrición Terapéutica S.L.",{"id":435,"slug":436,"hasResults":12,"nctId":437,"briefTitle":438,"officialTitle":439,"acronym":440,"eligibilityCriteria":441,"healthyVolunteers":442,"sex":90,"minAge":19,"maxAge":4,"enrollmentInfo":443,"targetDuration":4,"studyType":23,"phases":445,"briefSummary":446,"conditions":447,"keywords":453,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":455,"startDateStruct":457,"completionDateStruct":458,"leadSponsor":460,"locationsCount":83},"100609644","proactive-costs-of-care-study-100609644","NCT07217262","Proactive Costs of Care Study","An Open, Single-arm, Single-site Study to Evaluate the Proactive Costs of Care (PCOC) Intervention Delivered by a Trained Lay Educator to Test Feasibility With the Goal of Improving Self-efficacy Among Patients With Gynecologic Cancer on Active Therapy and Their Caregivers","PCOC","Inclusion Criteria for Patient Participants:\n\n* Individuals 18 years old or older are included.\n* Individuals diagnosed with gynecologic cancer\n* On active systemic therapy within 30 days of enrollment\n* Receiving treatment at Cedars-Sinai Medical Center\n* Can speak, read, and understand English\n\nInclusion Criteria for Caregiver Participants:\n\n\\- Caregivers to patients who satisfy the criteria above\n\nExclusion Criteria for Patient and Caregiver Participants:\n\n* Any patients whose records are flagged \"break the glass\" or \"research opt out.\"\n* Cannot speak, read, or understand English\n* Not willing to participate in the intervention or complete surveys",true,{"count":444,"type":22},36,[25],"The Proactive Costs of Care intervention is an educational intervention designed to help patients deal with the cost of cancer care. The main goal of this trial is to evaluate whether the Proactive Costs of Care intervention can be successfully delivered to cancer patients who are starting a new treatment and their caregivers by looking at how many participants complete the intervention. The other questions the trial aims to answer are whether the intervention can:\n\n* Improve confidence in solving problems related to costs of care\n* Reduce distress related to finances\n\nParticipants will complete the Proactive Costs of Care intervention, which is an approximately 30-minute one-time session with a lay educator reviewing the Proactive Costs of Care Guide and Cost Tracker. The intervention can be completed in person, by video, and by phone. Participants will also complete two surveys- one to be completed before the intervention and one to be completed 3 months after the intervention.",[448,449,450,451,28,452],"Financial Burden","Financial Toxicity","Financial Stress","Financial Navigation","Caregiver Burnout",[451,449,454,448,28,452],"Financial Distress",{"date":456,"type":45},"2026-02-10",{"date":236,"type":45},{"date":459,"type":22},"2027-04",{"name":461,"class":52},"Cedars-Sinai Medical Center",{"id":463,"slug":464,"hasResults":12,"nctId":465,"briefTitle":466,"officialTitle":467,"acronym":468,"eligibilityCriteria":469,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":470,"targetDuration":4,"studyType":23,"phases":472,"briefSummary":474,"conditions":475,"keywords":476,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":480,"lastUpdatePostDateStruct":481,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":487,"locationsCount":489},"100597235","phase-1-virtual-mindful-after-cancer-mac-intervention-to-promote-sexual-health-for-breast-and-gynecologic-cancer-survivors-100597235","NCT07055854","Virtual Mindful After Cancer (MAC) Intervention to Promote Sexual Health for Breast and Gynecologic Cancer Survivors","Virtual Mindful After Cancer Intervention to Promote Sexual Health for Breast and Gynecologic Cancer Survivors","MAC","Inclusion Criteria:\n\n* At least 18 years old\n* Diagnosed with female breast or gynecologic cancer at stage I-IV\n* Diagnosed at least 6 months ago\n* At least one sexual concern in a validated screener\n* Access to high speed internet via smart phone, tablet, and\u002For computer\n\nExclusion Criteria:\n\n• Those who do not comprehend English since the MAC program is only available in English.",{"count":471,"type":22},60,[473],"PHASE1","The goal of this study is to plan for a large scale evaluation of a program called Mindful After Cancer, or MAC. The MAC Program provides training in mindfulness, educational material about sexual health after cancer, and support to cancer survivors experiencing sexual and body image concerns.\n\nThe main study aims are to:\n\n1. Develop effective plans for recruiting participants across multiple sites\n2. Evaluate participation in the program and surveys\n3. Develop plans to train and supervise the professionals who will deliver the program.\n\nResearchers will compare study recruitment across three sites, aiming to identify the most efficient approach for a larger future trial.\n\nParticipants who are randomly assigned to receive the MAC program will receive access to the 8-week program delivered by a trained mindfulness coach using videoconference and online materials. They will asked to participate in an interview about their experiences at the end of the program.\n\nParticipants who are not randomly assigned to the MAC program will receive access to the program's educational materials after completing the final survey.\n\nAll study participants will be asked to complete 3 online surveys. Participants randomly assigned to the MAC Program will also be asked to complete a one-on-one interview about their experience in the program.",[28,179],[477,478,160,479],"cancer survivorship","mindfulness","intervention","2026-02-05",{"date":482,"type":45},"2026-02-09",{"date":484,"type":45},"2025-08-25",{"date":486,"type":22},"2027-05",{"name":488,"class":52},"Oregon State University",3,{"id":491,"slug":492,"hasResults":12,"nctId":493,"briefTitle":494,"officialTitle":495,"acronym":496,"eligibilityCriteria":497,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":498,"targetDuration":500,"studyType":176,"phases":4,"briefSummary":501,"conditions":502,"keywords":506,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":511,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":517,"locationsCount":361},"100615312","compliance-to-cervical-cancer-chemoradiation-guidelines-a-multicentric-implementation-audit-and-resource-assessment-initiative-of-national-cancer-grid-of-india-100615312","NCT07290972","Compliance to Cervical Cancer Chemoradiation Guidelines: A Multicentric Implementation Audit and Resource Assessment Initiative of National Cancer Grid of India","Compliance to Cervical Cancer Chemoradiation Guidelines: A Implementation Audit and Resource Assessment Initiative of National Cancer Grid of India","NCG-Compliance","The participating centers that agree to contribute data will include all registered cases over a 6 month period that have been diagnosed with histologically proven cervical cancer wherein either radical, adjuvant or palliative radiation with or without concurrent or systemic chemotherapy is planned.\n\nFurthermore any cases referred to the institution for brachytherapy alone will also be included.",{"count":499,"type":22},618,"3 Years","This is a combination of retrospective and prospective observational study that will be performed across NCG and other participating centers to report compliance to chemoradiation for cervical cancer. This audit will include patients treated with standard of care treatment, in this case definitive or adjuvant radiation+\u002F- concurrent chemotherapy will be included. Patients recruited in various institutions in prospective clinical trials will not be included. The participating centersthat agree to contribute data will include all registered cases over a 6-month period that have been diagnosed with cervical cancer wherein treatment is planned with radical dose radiation and\u002For concurrent chemotherapy. Centers that do not have retrospective data of the patients will contribute data of patients registered prospectively over 6 months. Furthermore, any cases referred to the institution for brachytherapy alone will also be included.\n\nAs a first step member institutions that participated in guideline development process or provide an agreement to guidelines adherence will be audited. The project will be submitted in institutional ethics committees with memorandum of understanding for anonymized data sharing.\n\nEach of the co-investigators listed from contributing centers will be directly responsible for collecting data contribution and accuracy of data submitted.\n\nThose centres which cannot or do not want to participate will be requested to provide data on only compliance outcomes to treatment for at least of 5 consecutively patients diagnosed with cervical cancer wherein treatment is planned with radical dose radiation and \u002For concurrent chemotherapy over a period of 6 months.",[503,28,504,505],"Cervical Cancer Screening","Treatment Compliance","Chemoradiotherapy",[229,134,507,508,509,505],"Recurrence","Treatment","Compliance","2026-02-03",{"date":512,"type":45},"2026-02-04",{"date":514,"type":45},"2021-02-01",{"date":516,"type":22},"2026-03-31",{"name":518,"class":264},"Tata Memorial Hospital",{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":524,"acronym":4,"eligibilityCriteria":525,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":526,"targetDuration":4,"studyType":23,"phases":528,"briefSummary":529,"conditions":530,"keywords":536,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":546,"locationsCount":83},"100609582","vaginal-dilator-therapy-after-pelvic-radiation-100609582","NCT07216456","Vaginal Dilator Therapy After Pelvic Radiation","Improving Engagement With Vaginal Dilator Therapy After Pelvic Radiation: A Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* female sex\n* adults aged 18 years or older\n* diagnosed with cancer of the anus, anal canal, anorectum, cervix, uterus, vagina, vulva, and\u002For bladder\n* completed pelvic radiation therapy in the past year\n* dilator therapy recommended by medical provider and standardized dilator received from provider\n* able to speak\u002Fread English\n\nExclusion Criteria:\n\n* aged less than 17 years\n* under the care of a pelvic floor physical therapist at the time of study enrollment\n* have a major\u002Fserious psychiatric concern (e.g., schizophrenia) as indicated by medical chart\u002Fmedical provider\n* inability to provide consent",{"count":527,"type":22},88,[25],"This study is testing a new program to help women who have had pelvic radiation therapy to use vaginal dilators more regularly. Vaginal dilators are important tools that can help prevent or treat vaginal narrowing (called vaginal stenosis), which can happen after radiation and make medical exams or sexual activity painful or difficult. Even though dilators are recommended, many women don't use them as often as needed.\n\nIn this study, 88 participants will be randomly assigned to one of two groups:\n\n* One group will receive the new behavioral program, which includes support and strategies to help with regular dilator use.\n* The other group will receive written educational materials (enhanced usual care).\n\nThe study will look at how often and how long participants use their dilators, and whether the program helps reduce symptoms like pain or emotional distress. Participants will complete surveys at the beginning of the study and again at 3, 6, and 9 months, plus short monthly check-ins.\n\nThe goal is to see if the program is helpful and easy to use, and to prepare for a larger study in the future.",[531,532,533,28,534,535],"Pelvic Radiotherapy","Vaginal Stenosis","Pelvic Cancer","Anorectal Cancer","Urologic Cancer",[537,538],"vaginal dilator therapy","pelvic radiation","2025-10-13",{"date":541,"type":45},"2025-10-15",{"date":543,"type":22},"2027-08-01",{"date":545,"type":22},"2030-04-30",{"name":547,"class":52},"Duke University",{"id":549,"slug":550,"hasResults":12,"nctId":551,"briefTitle":552,"officialTitle":552,"acronym":553,"eligibilityCriteria":554,"healthyVolunteers":12,"sex":18,"minAge":555,"maxAge":4,"enrollmentInfo":556,"targetDuration":4,"studyType":23,"phases":557,"briefSummary":558,"conditions":559,"keywords":560,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":566,"lastUpdatePostDateStruct":567,"startDateStruct":569,"completionDateStruct":571,"leadSponsor":572,"locationsCount":83},"100563715","esense-cancer-adapting-an-online-intervention-for-sexual-health-concerns-to-gynecologic-cancer-100563715","NCT06619769","eSense-Cancer: Adapting an Online Intervention for Sexual Health Concerns to Gynecologic Cancer","eSense-Cancer","Inclusion Criteria:\n\n* self-report a current or history of gynecologic cancer of any subtype\n* self-report symptoms of sexual difficulties and score of greater than 11 on the Female Sexual Distress Scale-Revised\n* are fluent in English (eSense content is delivered in English)\n* have reliable internet access and basic competency in using online platforms (individuals will self-report)\n* are available for 8 - 16 weeks and able to complete eSense modules and associated questionnaires\n* any gender\n\nExclusion Criteria:\n\n* have visual impairments or disabilities interfering with reading and ability to interact with online materials\n* have poorly managed anxiety or mood disorder (assessed using the degree of life interference evaluation at screening)\n* individuals who are in active treatment for their cancer (including radiation, chemotherapy and any planned surgeries).","19 Years",{"count":471,"type":22},[25],"Sexual health is a vital component of gynecologic cancer treatment and survivorship. Unfortunately, most gynecologic cancer survivors lack sufficient information about the impact of cancer on sexual health and treatment opportunities. This research aims to assess how well an adapted online health intervention meets the sexual health needs of gynecologic cancer survivors and to test the efficacy of the new platform. If successful, eSense-Cancer may increase access to treatment for gynecologic cancer survivors, including those living in remote areas or facing other accessibility barriers. It may also fill healthcare gaps for survivors of varying ethnicity, sexual orientation, socioeconomic status, and gender.",[28],[561,562,563,564,565],"behavioural intervention","mindfulness based therapy","cognitive behavioural therapy","digital health","eHealth","2025-09-20",{"date":568,"type":45},"2025-09-25",{"date":570,"type":45},"2024-10-01",{"date":405,"type":22},{"name":573,"class":52},"University of British Columbia",{"id":575,"slug":576,"hasResults":12,"nctId":577,"briefTitle":578,"officialTitle":579,"acronym":580,"eligibilityCriteria":581,"healthyVolunteers":12,"sex":90,"minAge":19,"maxAge":582,"enrollmentInfo":583,"targetDuration":4,"studyType":23,"phases":585,"briefSummary":586,"conditions":587,"keywords":596,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":606,"lastUpdatePostDateStruct":607,"startDateStruct":609,"completionDateStruct":611,"leadSponsor":613,"locationsCount":83},"100572340","optimal-perioperative-pain-control-in-minimally-invasive-abdominal-cancer-surgery-100572340","NCT06731998","Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery","Evaluating Optimal Perioperative Pain Management: A Prospective Randomized Control Trial of Laparoscopic Transversus Abdominis Plane Block With Local Anesthetic, Laparoscopic Transversus Abdominis Plane Block Alone, and Local Anesthetic Alone in Minimally Invasive Oncologic Surgery","LapTAP","Inclusion Criteria:\n\n1. Male and female patients age ≥ 18 - 89\n2. Patients scheduled for elective (clinically indicated) hepatic, gastric, biliary, pancreatic, gynecologic, colorectal, other GI Minimally invasive oncologic surgery.\n3. Patients who have provided informed consent to participate in the study.\n4. Patients with an American Society of Anesthesiologists (ASA) physical status classification of I, II, or III.\n5. Patients undergoing procedures anticipated to last more than 1 hour but less than 8 hours.\n6. Patients able to understand and self-report pain using the designated pain Visual Analog Scale\n\nExclusion Criteria:\n\n1. Patients age less than 18 or ≥ 90\n2. Pre-existing hepatic dysfunction, cirrhosis\n3. Patients with an ASA classification of IV or higher.\n4. Patients with chronic pain disorders or on long-term opioid or analgesic therapy.\n5. Patients with known contraindications to the study drugs or procedures (e.g., allergy to LA or contraindications to LapTAP).\n6. Patients with cognitive impairments or psychiatric conditions that could interfere with pain assessment or understanding of informed consent.\n7. Patients unable to understand the language in which consent and study-related information are provided (The study and the study-related information will be in the English Language)..\n8. Patients who have undergone major surgery within the last 6 months.\n9. Female patients who are pregnant.\n10. Patients currently enrolled in another clinical trial that might interfere with the outcome measures of this study.","89 Years",{"count":584,"type":22},48,[25],"This is a research study to evaluate the effectiveness of 3 different types of routine pain management regimens used during clinically indicated, minimally invasive oncologic (cancer) surgery. This project is considered \"Research\" and participation is voluntary. Upon enrollment in this study, the research team will collect data from the patient's medical records. The patient will undergo all of the normal testing and procedures required pre-operatively (standard of care). The study team will then randomly assign the patient (like a flip of a coin) to one of three different study arms for pain management during surgery:\n\n1. Laparoscopic Transversus Abdominis Plane Block (LapTAP) with Local Anesthetic (LA)\n2. Laparoscopic Transversus Abdominis Plane Block (LapTAP) only\n3. Local Anesthetic (LA) only The patient will receive standard pre- and post-operative care according to clinical guidelines (routine care). The study team will collect information from the patient's medical record for the first 24 hours after their surgery and upon discharge. This information will include pain scores, amount of medication required, any side effects the patient may have experienced, and satisfaction with pain control. Participation in the study will end upon discharge from the hospital.",[588,134,589,590,591,592,593,28,98,594,595],"Oncologic Surgery","Cancer Surgery","Hepatic Cancer","Gastric (Cardia, Body) Cancer","Biliary Tract Cancer","Pancreatic Cancer Resectable","Colorectal Cancer","Minimally Invasive Surgical Procedures",[597,598,599,600,601,602,603,604,605],"Laparoscopic Transversus Abdominis Plane Block","Local Anesthetic","Laparoscopic Surgical Procedure","pain management","cancer","cancer surgery","oncologic surgery","perioperative pain management","minimally invasive surgical procedures","2025-09-15",{"date":608,"type":45},"2025-09-18",{"date":610,"type":45},"2025-02-05",{"date":612,"type":22},"2026-12",{"name":614,"class":52},"Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)",{"id":616,"slug":617,"hasResults":12,"nctId":618,"briefTitle":619,"officialTitle":620,"acronym":621,"eligibilityCriteria":622,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":623,"targetDuration":4,"studyType":176,"phases":4,"briefSummary":625,"conditions":626,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":627,"lastUpdatePostDateStruct":628,"startDateStruct":630,"completionDateStruct":632,"leadSponsor":634,"locationsCount":4},"100588761","the-effect-of-previous-pregnancies-in-patients-with-gynecological-neoplasms-treated-with-pd-1pd-l1-inhibitors-100588761","NCT06945601","The Effect of Previous Pregnancies in Patients With Gynecological Neoplasms Treated With PD-1\u002FPD-L1 Inhibitors","Observational Study on the Effect of One or More Previous Pregnancies in Patients With Gynecological Neoplasms Treated With PD-1\u002FPD-L1 Inhibitors","FECONDE","Inclusion Criteria:\n\n* For patients past-pregnant and nulliparous:\n\n  * Age 18 years or older\n  * Female sex\n  * Confirmed cytological\u002Fhistological diagnosis of endometrial or cervical cancer\n  * Treatment with ICI monotherapy or in combination with chemotherapy\n  * Written informed consent for living patients Only for patients past-pregnant:\n  * Available obstetric history\n\nExclusion Criteria:\n\n* Not eligible for treatment with ICI either in monotherapy or in combination with chemotherapy.",{"count":624,"type":22},150,"Despite the fact that immunotherapy has radically changed the therapeutic landscape in multiple types of tumors, to date the only predictive factor for response to treatment with immune checkpoint inhibitors (ICI), although with many limitations and very different specificity among different pathologies, remains the expression of PD-L1. Several meta- analyses of randomized studies have shown that the female sex is associated with less benefit compared to the male sex in patients with melanoma and NSCLC. Reviewing the available data in the literature, this reduced efficacy is confirmed only in the mono- immunotherapy settings, while when chemo-immune combinations are administered, women seem to benefit more than men. Pregnancy, being associated with immunological changes that can last over time (e.g., mechanisms of immuno-tolerance, antigen sharing between the placenta and neoplasia, fetal microchimeric cells, etc.), could partly explain the impact of sex on the outcome of immune checkpoint inhibitors. In particular, some mechanisms of immunotolerance, such as the increase of T-regulatory cells specific to oncofetal antigens in the endometrium, could potentially suggest a lower efficacy of immunotherapy in women. The current study, by characterizing the impact of previous pregnancies on oncological outcomes, could contribute to providing the basis for future research aimed at defining the biological mechanisms underlying the effect of pregnancy on the immune system and the efficacy of immune checkpoint inhibitors.\n\nThe study has an observational, retrospective\u002Fprospective, multicenter design. Female patients with endometrial and cervical cancer will be included. All these patients will be treated with ICIs either as monotherapy or in combination with chemo-immunotherapy. Clinical and oncological anamnesis information will be collected for each patient (type of neoplasm, line of therapy, age at the start of therapy, weight, height, smoking habits, comorbidities, performance status, number and site of metastases, concomitant non- oncological therapies); anatomical-pathological parameters will also be collected (level of PD-L1 expression, molecular and mutational profile of the tumor). Additionally, information regarding the woman's pregnancy and fertility history will be gathered (age at menarche\u002Fmenopause, number of pregnancies, age at first pregnancy, age at last pregnancy, any HRT or contraceptive therapy, any gynecological surgery).",[28],"2025-04-18",{"date":629,"type":45},"2025-04-25",{"date":631,"type":22},"2025-05",{"date":633,"type":22},"2030-05",{"name":635,"class":52},"IRCCS San Raffaele",{"id":637,"slug":638,"hasResults":12,"nctId":639,"briefTitle":640,"officialTitle":641,"acronym":642,"eligibilityCriteria":643,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":644,"targetDuration":4,"studyType":176,"phases":4,"briefSummary":646,"conditions":647,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":648,"lastUpdatePostDateStruct":649,"startDateStruct":651,"completionDateStruct":653,"leadSponsor":655,"locationsCount":83},"100586819","attitudes-to-gynae-oncology-care-location---graceful-100586819","NCT06920342","Attitudes to Gynae Oncology Care Location - GRACEFUL","Investigating Attitudes to Gynaecological Rapid Access, Cancer Exclusion and Follow Up Location (GRACEFUL Study)","GRACEFUL","Inclusion Criteria:\n\n\\- Female Aged 18 or over Able to give informed consent Have been referred to secondary care with a suspected gynaecological cancer, or have previously been diagnosed with a gynaecological malignancy\n\nExclusion Criteria:\n\n\\- Male Unable to give informed consent",{"count":645,"type":22},600,"Gynaecological oncology (cancer) place of care is often based on evolution of services, along historical professional boundaries, rather than user needs or preferences. The investigators aim to gather views of patients in the United Kingdom (UK) on their preferred place of care for investigation, treatment and follow-up of gynaecological cancer. An initial scoping review found no previous work in this area. Pilot work, performed to inform local re-organisation of services, found that 53% of participants were somewhat or very unhappy to have care co-located with O\\&G services. Specifically, two key themes were identified through content analysis of free-text comments: \"environment and getting this right is vital\"; and \"our cancer should be the priority\".\n\nHowever, via a BGCS survey, the investigator found that healthcare professionals (HCPs) underestimated strong patient preferences. Of those who see patients within O\\&G services, only 50% said patients were seen at separate times\u002Flocations from obstetric patients. The investigators want to expand on these pilot data to better understand how to design services that better meet our patients' needs. The investigators will conduct a survey to ascertain service users' attitudes to location of services, collecting quantitative data \\& qualitative data, including opportunities for feedback in free text. The investigator will conduct analysis using standard statistical methods \\& content analysis of free-text responses. Submissions will be anonymous \\& no identifiable data will be collected routinely, unless volunteered by the respondent. The investigator will ask a subset of \\~30 participants to undertake a telephone\u002Fvirtual-based semi-structured interview to further explore understanding on attitudes to location of care more generally. A topic guide will be developed, informed by the Theoretical Framework of Acceptability. Interviews will be audio-recorded with consent, transcribed verbatim \\& anonymised. The anonymised transcripts will be analysed using a form of Thematic Analysis. These findings should help to shape future health care service sensitive to patient need.",[28],"2025-04-07",{"date":650,"type":45},"2025-04-09",{"date":652,"type":45},"2025-03-24",{"date":654,"type":22},"2029-02-02",{"name":656,"class":52},"Somerset NHS Foundation Trust",{"id":658,"slug":659,"hasResults":12,"nctId":660,"briefTitle":661,"officialTitle":662,"acronym":663,"eligibilityCriteria":664,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":665,"targetDuration":4,"studyType":23,"phases":666,"briefSummary":668,"conditions":669,"keywords":674,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":680,"lastUpdatePostDateStruct":681,"startDateStruct":683,"completionDateStruct":685,"leadSponsor":687,"locationsCount":83},"100583089","phase-4-near-infrared-fluorescence-imaging-with-indocyanine-green-to-evaluate-bowel-anastomoses-in-gynecologic-oncology-surgery-100583089","NCT06871787","Near-Infrared Fluorescence Imaging With Indocyanine Green to Evaluate Bowel Anastomoses in Gynecologic Oncology Surgery","Evaluation of Bowel Anastomoses During Gynecologic Oncology Surgery Using Near-Infrared Fluorescence Imaging With Indocyanine Green","INOCA","Inclusion Criteria:\n\n* Female patients aged 18 years or older.\n* Diagnosis of gynecologic cancer (ovarian, endometrial, cervical, vulvar) requiring surgical treatment.\n* Planned bowel resection and anastomosis during gynecologic oncology surgery.\n* Ability and willingness to provide informed consent.\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to indocyanine green (ICG).\n* Pregnancy or breastfeeding at the time of surgery.\n* Severe liver or kidney dysfunction limiting the use of ICG.",{"count":92,"type":22},[667],"PHASE4","The goal of this study is to evaluate if indocyanine green (ICG) fluorescence imaging helps reduce complications in bowel surgery performed during gynecologic cancer operations.\n\nThe main question it aims to answer is: Does using ICG fluorescence imaging during bowel anastomosis reduce the rate of complications such as leaks, infections, and abscesses within 30 days after surgery? Participants are women aged 18 and older undergoing surgery for gynecologic cancers (such as ovarian, uterine, cervical, or vulvar cancer). During surgery, investigators will inject ICG intravenously, then use a special near-infrared camera to see how well blood flows at the anastomosis site. The investigators will then decide if the reconnection is good enough or needs adjustment.\n\nResearchers will record any complications within the first 30 days after surgery to understand if this imaging method helps reduce surgical risks.",[28,180,670,671,672,673],"Endometrial Cancers","Cervical Cancers","Vulvar Cancer","Anastomotic Leaks",[675,676,677,311,678,679],"Indocyanine Green","Near-Infrared Imaging","Bowel Anastomosis","Anastomotic Complications","Perfusion Assessment","2025-03-11",{"date":682,"type":45},"2025-03-14",{"date":684,"type":22},"2025-09-01",{"date":686,"type":22},"2027-12-30",{"name":688,"class":52},"Istanbul University",{"id":690,"slug":691,"hasResults":12,"nctId":692,"briefTitle":693,"officialTitle":694,"acronym":695,"eligibilityCriteria":696,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":697,"targetDuration":4,"studyType":23,"phases":698,"briefSummary":699,"conditions":700,"keywords":707,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":711,"lastUpdatePostDateStruct":712,"startDateStruct":714,"completionDateStruct":716,"leadSponsor":718,"locationsCount":361},"100579306","pelvic-health-rehabilitation-after-breast-and-gynecologic-cancer-100579306","NCT06822582","Pelvic Health Rehabilitation After Breast and Gynecologic Cancer","A Pelvic Health eModule to Address Urogenital Impairments After Breast and Gynecologic Cancer: a Pilot Prospective Interventional Study","GYVE","Inclusion Criteria:\n\n* be \\>18 years of age;\n* have received a diagnosis of breast or gynecological (endometrial, cervical, ovarian, vulvar or vaginal) cancer (Stage I-IV) ;\n* be on active cancer treatment or have completed any cancer treatment (surgery and\u002For radiation therapy and\u002For chemotherapy) within the last 3 years;\n* be able to provide informed written consent in English or French;\n* have a urogenital dysfunction, as screened by a score of ≥ 2 on the Pelvic Floor Bother Questionnaire.\n\nExclusion Criteria:\n\n* do not have regular access to internet, to a smart device or a computer, at home.",{"count":250,"type":22},[25],"The GYVE study aims at testing an online program (eModule) to help people who have had breast or gynecologic cancer and are experiencing pelvic health issues like urinary incontinence and pain during sex. These cancers and their treatments can cause significant pelvic health problems, affecting daily life and quality of life. Physiotherapy can help, but access is often limited due to costs and other barriers. The study will involve 20 participants from Quebec and Edmonton, who will take part in a 12-week program with weekly online group sessions led by a physiotherapist. Topics include pelvic floor muscle training, use of vaginal moisturizers, hydration, diet, and pain management. Led by experts in cancer rehabilitation and pelvic health, the study aims to provide valuable information on the feasibility and effectiveness of the eModule, potentially leading to broader implementation to help more people with lived experience of cancer.",[28,701,702,703,704,705,706],"Breast Cancer Female","Incontinence","Incontinence Bowel","Sexual Dysfunction","Vaginal Atrophy, Sexual Dysfunction, Vaginal Dryness, Dyspareunia","Constipation",[708,709,710],"pelvic health","telerehabilitation","supportive cancer care","2025-02-11",{"date":713,"type":45},"2025-02-12",{"date":715,"type":45},"2025-01-07",{"date":717,"type":22},"2026-06",{"name":719,"class":52},"Laval University",{"id":721,"slug":722,"hasResults":12,"nctId":723,"briefTitle":724,"officialTitle":724,"acronym":4,"eligibilityCriteria":725,"healthyVolunteers":12,"sex":18,"minAge":726,"maxAge":4,"enrollmentInfo":727,"targetDuration":4,"studyType":176,"phases":4,"briefSummary":729,"conditions":730,"keywords":732,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":739,"lastUpdatePostDateStruct":740,"startDateStruct":742,"completionDateStruct":744,"leadSponsor":746,"locationsCount":83},"100567769","near-infrared-spectroscopy-nirs-as-a-method-for-measuring-oxidative-capacity-of-skeletal-muscle-mitochondria-in-breast-cancer-and-all-gynecological-cancer-patients-100567769","NCT06672497","Near Infrared Spectroscopy (NIRS) as a Method for Measuring Oxidative Capacity of Skeletal Muscle Mitochondria in Breast Cancer and All Gynecological Cancer Patients","Inclusion Criteria:\n\n* Patients diagnosed with breast cancer or gynecological cancer without distance metastasis\n* Able to perform exercise on a stationary cycle ergometer at moderate intensities for a maximum of 15 minutes\n* Hemoglobin values greater than 10 at baseline\n* ALT and AST values less than 2.5X the upper limit of normal by institutional standards\n* Godin-Shepard Leisure time Physical Activity Questionnaire (GLTEQ) score of 14 or greater will be included. A score of less than 14 is considered insufficiency active\u002Fsedentary\n\nExclusion Criteria:\n\n* Metastatic breast or gynecological cancer\n* Clinically advanced cardiovascular disease\n* Clinically advanced pulmonary disease\n* Disease requiring continuous oxygen supplementation\n* Greater than 2 centimeters or more of subcutaneous adipose tissue on the anterior thigh\n* Inability to walk or stand\n* Movement disorders\n* Spinal cord injuries\n* Autoimmune disorders\n* Pregnant or breastfeeding\n* Mini-Mental State Examination (MMSE) \\\u003C24","20 Years",{"count":728,"type":22},30,"Participants recruited for this study will be breast cancer or gynecological cancer patients who agree to participate in an exercise study examining the effects of chemotherapy on muscle mitochondrial oxidative capacity, a measure of skeletal muscle health. Participants will ride a stationary bicycle and the quadriceps muscle will be non-invasively evaluated.",[179,28,731],"Mitochondrial Function",[733,734,735,736,737,738],"nirs","mitochondrial oxidative capacity","muscle oxidative capacity","breast cancer","gynecological cancer","near infrared spectroscopy","2024-11-01",{"date":741,"type":45},"2024-11-04",{"date":743,"type":45},"2021-09-07",{"date":745,"type":22},"2026-03",{"name":747,"class":52},"University of South Carolina"]